摘要
Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.
| 貢獻的翻譯標題 | 去整合蛋白變異體及其醫藥用途 |
|---|---|
| 原文 | English |
| 專利號 | 60/871,854 |
| 出版狀態 | Published - 2009 7月 23 |